Chapter 6 │ Page 217 70. Mahoney, E., et al., Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies. Leuk Lymphoma, 2013. 54(12): p. 2685-92. 71. Jaskulska, A., A.E. Janecka, and K. Gach-Janczak, Thapsigargin-From Traditional Medicine to Anticancer Drug. Int J Mol Sci, 2020. 22(1). 72. Hassannia, B., et al., Withaferin A: From ayurvedic folk medicine to preclinical anticancer drug. Biochemical Pharmacology, 2020. 173: p. 113602. 73. Formica, V., et al., PD-L1 thresholds predict e icacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials. ESMO Open, 2024. 9(11). 74. Bill, R., W.C. Faquin, and S.I. Pai, Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations. Head Neck Pathol, 2023. 17(4): p. 969-975. 75. Paolino, G., et al., PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. Pathology - Research and Practice, 2021. 226: p. 153605. 76. Maja, M. and D. Tyteca, Alteration of cholesterol distribution at the plasma membrane of cancer cells: From evidence to pathophysiological implication and promising therapy strategy. Front Physiol, 2022. 13: p. 999883. 77. Durán Martínez, D., et al. Studies of Applications of Cold Plasma Systems in Cancer Treatment: Mechanisms of Oxidant Stress and Pathway Signaling. Stresses, 2024. 4, 896-915 DOI: 10.3390/stresses4040060. 78. Lin, A., et al., Toward defining plasma treatment dose: The role of plasma treatment energy of pulsed-dielectric barrier discharge in dictating in vitro biological responses. Plasma Processes and Polymers, 2022. 19(3): p. e2100151.
RkJQdWJsaXNoZXIy MTk4NDMw